Celerion’s European team is committed to service excellence and is focused on helping clients get their products to market faster. They are led by a management team that has extensive depth and breadth in drug development.
Learn more about any Celerion team member by clicking below.
Ms. McNeilly is Site Director of Celerion’s Global Clinical Research facility in Belfast, Northern Ireland UK. She has overall responsibility for operational execution and management of all clinical studies conducted in Belfast. During her tenure, Ms. McNeilly has successfully grown the business and expanded the range of services at the Belfast facility to include more complex studies in a variety of therapeutic areas.
Ms. McNeilly has over 20 years experience in clinical research providing her with in-depth understanding of client challenges and enables her to optimize solutions for study success. Other achievements include the development of a highly successful study recruitment team whose performance is industry leading and drives a culture where quality in study execution is a given.
Additionally, she has also led the efforts to build a successful network of local medical experts including primary care physicians and various key opinion leaders within both academia and the National Health Service.
Ms. McNeilly has held similar positions of increasing responsibility within the UK for MDS Pharma Services, Harris Laboratories and was European Director of Clinical Operations for sites throughout Germany. During this time Ms. McNeilly has served as company director for MDS Pharma Services, Harris Laboratories Gb, Genapta and currently Celerion.
Ms. McNeilly holds an MBA, a B.Sc and several post graduate qualifications and is an active member of the Royal Society of Philosophy.
As Senior Vice President of Global Clinical Development, Dr. Klaus Fischer leads a global group of clinical development professionals focused on the execution of clinical studies in patients. Very experienced in clinical project management and monitoring, these teams work with clinical sites and alliance partners on a global scale to generate key development data for critical decisions about whether or not to progress new drugs or treatment concepts to the market. These clinical development professionals leverage drug development and regulatory knowledge, bioanalytical expertise, data analysis and medical writing expertise within Celerion to provide complete solutions for clients’ clinical development needs.
Combining advanced training in pharmacy and business administration, Dr. Fischer brings to his role 20 years of experience in new product development, clinical study management, medical marketing and executive leadership with Hoechst, Hoechst-Roussel, Aventis and as the CEO of the Assign Group. In this capacity, Dr. Fischer founded the company in Europe and built the organization into an efficient clinical research operation with a track record in managing regional and global clinical studies. Over the years he and his colleagues have worked on several oncology treatments, vaccines, and other medicines that have progressed into late stage development and the marketplace.
Dr. Fischer has given numerous invited lectures at scientific meetings and academic institutions. He received his scientific degree from Ludwig-Maximilian-University in Munich.
Dr. Cromie serves as the European Director of Clinical Pharmacology Sciences within one of the largest and most experienced global groups of its kind in industry. Based in the UK, she is responsible for all European Sponsor deliverables in the areas of modeling and simulation, study design and protocol development, biostatistics, pharmacokinetics, and medical writing. Dr. Cromie is also responsible for ensuring European standards and regulatory requirements are an integral part of the harmonised global processes within Celerion’s global Clinical Pharmacology Sciences group. In her role, Dr. Cromie provides European Sponsors with the opportunity of taking advantage of Celerion’s large global clinical presence while working consistently with a European Clinical Pharmacology Sciences team across drug development programs.
Dr. Cromie has over 15 years experience in early clinical research, providing her with an in-depth understanding of the clinical pharmacology challenges faced by clients. She has extensive experience in study design, with publications and presentations in the areas of study design, safety, PK and efficacy of new compounds. Her current focus is on innovative and adaptive study designs to increase clinical trial efficiency and accelerate drug development decisions.
Dr. Cromie joined MDS Harris in 1996 and held positions of increasing responsibility within the Clinical Pharmacology Sciences department before taking on her current role in 2007. She has a BSc in Biology and a PhD in Zoology both from The Queen’s University of Belfast.
Petra Struwe is the Site Director of the Celerion Bioanalytical Services facility in Zurich, Switzerland. She is responsible for all bioanalytical operations, focusing on the strategic and tactical management of the LC-MS/MS and Ligand Binding Services groups. In this role Dr Struwe has successfully grown these businesses and implemented a range of new technologies to drive efficiency and increase throughput.
Dr. Struwe has over 15 years experience in bioanalysis, developing and validating a variety of assays with both small and large molecules. This expertise has provided an in-depth understanding of client challenges and enables her to effectively develop solutions that deliver results.
Under Dr. Struwe’s leadership, the bioanalytical laboratory in Zurich has one of the largest Ligand Binding Services facilities in the world with over 25 years experience. By investing in the right automation technology, the team has maximized throughput and regularly analysed up to 200,000 samples annually. Dr. Struwe is focused on exploring innovative technologies and most recently has led the efforts to implement Dried Blood Spots (DBS) for both small and large molecules.
Dr. Struwe previously held the roles of Site Director and Director of Chromatography with MDS Pharma Services. She has international experience having held roles with Solvay Pharmaceuticals in Hannover, Germany; Okayama University of Science, Japan; and Physikalisch-technische Bundesanstalt, Braunschweig, Germany.
Dr. Struwe holds a PhD and diploma in chemistry from TH University Karlsruhe, Germany. She is an active member of the European Bioanalytical Forum (EBF) for small molecules and also participates in the Global CRO Council (GCC) and Global Bioanalytical Consortium (GBC).
As Executive Director of Business Development, Mr. Gerbet leads the European sales organization. In this role he is focused on developing and driving strategies targeted on the specific needs of a European client base. Mr. Gerbet passionately represents the voice of European clients internally and has successfully implemented corporate and commercials solutions to meet these needs.
Prior to this role Mr. Gerbet headed up the Business Development team in Europe as well as being the Head of the INC Research office in France. He implemented successful strategies that led to significantly exceeding sales targets. Prior to the acquisition by INC Research, Mr. Gerbet was Senior Director/ President of MDS Pharma Services’ operation in France. He was responsible for leading all sales efforts as well as having responsibility for the French Leadership team and Work Council.
Mr. Gerbet has also held Sales and Marketing roles of increasing responsibility in the in vitro diagnostics business that included Biochem Immunosystems (previously Serono Diagnostics) and BAYER Diagnostics amongst others.
With over 25 years experience in sales and marketing within the life sciences, Mr. Gerbet has spent 15 of those at contract research organizations. He has also held key leadership positions in Europe for over 10 years for global organizations, always ensuring the needs of his customers are accurately represented.
Mr. Gerbet is a trained Pharmacist at the University Paris XI, France and taught Applied Research in Statistics, Mathematics and Computing at PhD level.